Aydin Huseynov
Stock Analyst at Ladenburg Thalmann
(0.71)
# 4,013
Out of 5,022 analysts
58
Total ratings
32%
Success rate
-25.47%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Aydin Huseynov
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARDX Ardelyx | Assumes: Buy | $11 | $5.01 | +119.56% | 1 | Mar 7, 2025 | |
| URGN UroGen Pharma | Assumes: Buy | $31 | $16.76 | +84.96% | 1 | Feb 19, 2025 | |
| MRKR Marker Therapeutics | Maintains: Buy | $11 → $19 | $1.02 | +1,762.75% | 2 | Oct 21, 2024 | |
| CRVS Corvus Pharmaceuticals | Maintains: Buy | $12 → $21 | $7.11 | +195.36% | 3 | Sep 16, 2024 | |
| CMPX Compass Therapeutics | Upgrades: Buy | $5 | $4.29 | +16.69% | 2 | Sep 16, 2024 | |
| ACRV Acrivon Therapeutics | Upgrades: Buy | $16 | $1.77 | +803.95% | 3 | Sep 16, 2024 | |
| CLDI Calidi Biotherapeutics | Initiates: Buy | $120 | $1.63 | +7,261.96% | 1 | Jun 27, 2024 | |
| CAPR Capricor Therapeutics | Maintains: Buy | $24 → $25 | $6.72 | +272.02% | 2 | May 14, 2024 | |
| SPRB Spruce Biosciences | Downgrades: Neutral | n/a | $159.01 | - | 3 | Mar 14, 2024 | |
| BDRX Biodexa Pharmaceuticals | Initiates: Buy | $2,000 | $7.83 | +25,442.78% | 1 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7 | $1.32 | +430.30% | 1 | Dec 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $3.86 | +159.07% | 1 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $15.55 | +285.85% | 1 | Sep 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $6 | $1.80 | +233.33% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $4.66 | +114.59% | 3 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $375 → $240 | $1.85 | +12,872.97% | 2 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $104 → $182 | $11.53 | +1,478.49% | 2 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Speculative Buy | $180 → $80 | $0.44 | +18,036.48% | 1 | Apr 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $4.16 | +380.77% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $6.35 | - | 4 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.53 | - | 2 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $2.32 | +158.62% | 1 | Jul 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $6.16 | +240.91% | 1 | Jul 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10,500 | $14.86 | +70,559.49% | 1 | May 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $37 | $1.66 | +2,128.92% | 1 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $300 | $57.40 | +422.65% | 3 | Nov 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $557.73 | - | 6 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $89 | $84.73 | +5.04% | 2 | Jul 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | n/a | $137.35 | - | 1 | Sep 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Speculative Buy | $15,000 | $3.96 | +378,687.88% | 1 | Jun 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $336 | $2.47 | +13,503.24% | 1 | May 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $4.89 | +268.10% | 1 | Mar 19, 2020 |
Ardelyx
Mar 7, 2025
Assumes: Buy
Price Target: $11
Current: $5.01
Upside: +119.56%
UroGen Pharma
Feb 19, 2025
Assumes: Buy
Price Target: $31
Current: $16.76
Upside: +84.96%
Marker Therapeutics
Oct 21, 2024
Maintains: Buy
Price Target: $11 → $19
Current: $1.02
Upside: +1,762.75%
Corvus Pharmaceuticals
Sep 16, 2024
Maintains: Buy
Price Target: $12 → $21
Current: $7.11
Upside: +195.36%
Compass Therapeutics
Sep 16, 2024
Upgrades: Buy
Price Target: $5
Current: $4.29
Upside: +16.69%
Acrivon Therapeutics
Sep 16, 2024
Upgrades: Buy
Price Target: $16
Current: $1.77
Upside: +803.95%
Calidi Biotherapeutics
Jun 27, 2024
Initiates: Buy
Price Target: $120
Current: $1.63
Upside: +7,261.96%
Capricor Therapeutics
May 14, 2024
Maintains: Buy
Price Target: $24 → $25
Current: $6.72
Upside: +272.02%
Spruce Biosciences
Mar 14, 2024
Downgrades: Neutral
Price Target: n/a
Current: $159.01
Upside: -
Biodexa Pharmaceuticals
Feb 8, 2024
Initiates: Buy
Price Target: $2,000
Current: $7.83
Upside: +25,442.78%
Dec 27, 2023
Initiates: Buy
Price Target: $7
Current: $1.32
Upside: +430.30%
Oct 10, 2023
Initiates: Buy
Price Target: $10
Current: $3.86
Upside: +159.07%
Sep 22, 2023
Initiates: Buy
Price Target: $60
Current: $15.55
Upside: +285.85%
Aug 14, 2023
Maintains: Buy
Price Target: $10 → $6
Current: $1.80
Upside: +233.33%
Jun 5, 2023
Maintains: Buy
Price Target: $20 → $10
Current: $4.66
Upside: +114.59%
May 16, 2023
Maintains: Buy
Price Target: $375 → $240
Current: $1.85
Upside: +12,872.97%
Apr 28, 2023
Maintains: Buy
Price Target: $104 → $182
Current: $11.53
Upside: +1,478.49%
Apr 4, 2023
Maintains: Speculative Buy
Price Target: $180 → $80
Current: $0.44
Upside: +18,036.48%
Mar 7, 2023
Initiates: Buy
Price Target: $20
Current: $4.16
Upside: +380.77%
Nov 4, 2022
Downgrades: Neutral
Price Target: n/a
Current: $6.35
Upside: -
Aug 23, 2022
Downgrades: Neutral
Price Target: n/a
Current: $1.53
Upside: -
Jul 27, 2022
Initiates: Buy
Price Target: $6
Current: $2.32
Upside: +158.62%
Jul 13, 2022
Initiates: Buy
Price Target: $21
Current: $6.16
Upside: +240.91%
May 6, 2022
Initiates: Buy
Price Target: $10,500
Current: $14.86
Upside: +70,559.49%
May 2, 2022
Initiates: Buy
Price Target: $37
Current: $1.66
Upside: +2,128.92%
Nov 8, 2021
Upgrades: Buy
Price Target: $300
Current: $57.40
Upside: +422.65%
Nov 5, 2021
Downgrades: Hold
Price Target: n/a
Current: $557.73
Upside: -
Jul 20, 2021
Upgrades: Buy
Price Target: $89
Current: $84.73
Upside: +5.04%
Sep 30, 2020
Initiates: Hold
Price Target: n/a
Current: $137.35
Upside: -
Jun 16, 2020
Initiates: Speculative Buy
Price Target: $15,000
Current: $3.96
Upside: +378,687.88%
May 21, 2020
Initiates: Buy
Price Target: $336
Current: $2.47
Upside: +13,503.24%
Mar 19, 2020
Initiates: Buy
Price Target: $18
Current: $4.89
Upside: +268.10%